Question · from the living review of Hypertension Management →

Is it true that primary aldosteronism is an under-diagnosed cause of resistant hypertension?

Likely updated weekly · as of

Priors rates this Likely — 79 out of 100, updated weekly. Probably — but it is not fully settled. On the claim that primary aldosteronism is an under-diagnosed cause of resistant hypertension, its four-agent AI review panel weighs 8 primary peer-reviewed studies.

RefutedDoubtfulUncertainLikelyEstablished
where this sits on Priors’ scale of how settled the evidence is

How we got this answer. Priors runs each claim through a panel of four AI agents, each acting as a specialist expert reviewer. They read the published, peer-reviewed studies behind the question, judge how strong, consistent and reliable the evidence is, and turn that judgment into a single rating from 0 to 100 — refreshed every week as new studies appear, so it reflects where the evidence stands today, not a one-off verdict.

The traceable studies behind this rating — and the panel’s single strongest counter-argument to it — are in Priors’ full Hypertension Management review.

Related Cardiovascular questions

Is it true that SGLT2 inhibitors reduce CKD progression in type 2 diabetes? → Is it true that dual RAAS blockade increases hyperkalaemia and acute kidney injury risk? → Is it true that finerenone reduces cardiovascular and renal events in CKD with T2D? → Is it true that spironolactone outperforms other agents as 4th-line in resistant hypertension? →
Reflects the peer-reviewed evidence as of 17 July 2026 and updates as new studies land. AI can make mistakes. Not medical advice.